20-F: Ehave 2025 Annual Report: Financial & Operational Review

Ehave, Inc. reports a net loss of $3.76 million for 2025 while highlighting ongoing going concern risks and material weaknesses in internal controls.

Summary

• Reported a net loss of $3,756,479 for the fiscal year ended December 31, 2025, compared to a $2,748,874 loss in 2024.
• Generated minimal revenue of $2,183 in 2025, with no significant revenue in 2024.
• Accumulated deficit reached $40,767,900 as of December 31, 2025.
• Working capital deficit stands at $12,342,855.
• Total assets increased to $3,701,771, primarily due to intangible asset acquisitions.
• Management identified material weaknesses in internal controls over financial reporting, specifically regarding segregation of duties and accounting oversight.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly distressed financial situation characterized by recurring losses, significant going concern warnings, and unresolved material weaknesses in internal controls.

Positives

• Acquisition of new intellectual property assets, including the AIHeadhunter platform, to drive future growth.
• Continued development of the Ehave Dashboard and expansion of the KetaDash subsidiary.
• Maintained operations through strategic equity and debt financing despite significant liquidity constraints.

Negatives

• Substantial doubt regarding the ability to continue as a going concern.
• Significant and widening net losses year-over-year.
• Material weaknesses in internal control over financial reporting remain unresolved.
• Limited liquidity with a working capital deficit exceeding $12 million.
• Reliance on third-party data centers and potential regulatory hurdles for future medical device commercialization.

Risks

• Inability to raise sufficient capital to fund operations through the fourth quarter of 2026.
• Potential delisting or lack of liquidity on the Pink Open Market.
• Risk of intellectual property infringement claims and costly litigation.
• Stringent regulatory requirements (FDA, HIPAA) for digital health and psychedelic-related products.
• Dependence on key management personnel and consultants.
• Cybersecurity risks related to the storage and transmission of sensitive patient health information.

Future Outlook

Management intends to continue the commercialization of MegaTeam, NinjaReflex, and KetaDash products while seeking additional capital through equity and debt financing to fund operations through 2026. The company plans to leverage its mental health informatics platform and recently acquired assets to optimize patient outcomes.

Management Comments

• Management acknowledges substantial doubt regarding the company's ability to continue as a going concern.
• Management intends to resolve identified material weaknesses in internal controls by maintaining sufficient accounting personnel and documenting procedures.

Industry Context

StockSavvy.ai notes that Ehave operates in the highly volatile and capital-intensive digital therapeutics and psychedelic-assisted therapy space. The company's struggle to generate revenue while maintaining high administrative costs is consistent with early-stage firms in this sector, though the reliance on 'going concern' financing highlights significant operational fragility compared to better-capitalized competitors.

Comparison to Industry Standards

• Unlike established digital health firms (e.g., Akili Interactive), Ehave lacks significant commercial revenue and relies heavily on debt/equity dilution.
• The company's reliance on third-party data centers and lack of physical clinics for KetaDash differentiates its cost structure from competitors like Field Trip Health.
• Internal control weaknesses are common in micro-cap companies but represent a significant governance gap compared to industry standards for public reporting.

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Consulting agreements with CEO Benjamin Kaplan.
• Note payable to a major shareholder for $165,000.
• Accrued expenses related to executive employment agreements.

Stakeholder Impact

• Shareholders face significant dilution risk from future capital raises.
• Creditors face risks associated with the company's default on convertible notes.
• Employees and consultants are dependent on the company's ability to secure funding.

Next Steps

• Continue efforts to raise additional capital to fund operations.
• Work toward remediating material weaknesses in internal control over financial reporting.
• Advance clinical research and commercialization of the Ehave Dashboard and KetaDash services.
• Seek stockholder approval for the 2026 Equity Incentive Plan.

Key Dates

Recommendation

The company's severe liquidity issues, history of operating losses, and unresolved material weaknesses in internal controls present an extremely high risk for investors, with little evidence of a clear path to profitability.

Keywords

Ehave, digital therapeutics, mental health, KetaDash, psychedelic medicine, ADHD, AI, biotech